UKRAINE – 2021/02/27: In this photo illustration a Regeneron Pharmaceuticals logo of a US … [+]
The stock price of Regeneron has seen a 16% fall over the last twenty-one trading days, while it is down 6% over the last year. The volatility in REGN stock is being driven by the developments for REGEN-COV, its Covid-19 antibody cocktail. REGN stock plunged 6% in Friday (Oct 1) trade after Merck announced positive data for its Covid-19 antiviral oral pill. The positive data for Merck sent many vaccine stocks to lower levels, due to fears of vaccine sales declining sooner than earlier anticipated. Regeneron has developed an effective treatment for Covid-19, which is also recommended by the WHO, but it is priced much higher at $1,250 per dose, compared to $700 per patient cost for Merck’s oral pill. Although Merck’s pill is not as effective as Regenron’s, the price point may result in more takers for Merck’s pill, and this has led to a decline in REGN stock.
However, now that REGN stock has seen a decline of 16% in twenty-one trading days, will it continue its downward trajectory, or is a rise imminent? Going by historical performance, there is a higher chance of a decline in REGN stock over the next month. Out of 50 instances in the last ten years that REGN stock saw a twenty-one day decline of 16% or more, 30 of them resulted in REGN stock declining over the subsequent one month period (twenty-one trading days). This historical pattern reflects 30 out of 50, or about 60% chance of a drop in REGN stock over the coming month. See our analysis on Regeneron Stock Chance of A Rise for more details.
So, if this follows historical performance, it is likely that REGN stock will fall to lower levels going forward. However, if you are considering REGN stock as an investment over a longer time frame, you can explore our forecast for Regeneron valuation of $530 per share, implying over 7% discount from its current levels of around $570.
Calculation of ‘Event Probability‘ and ‘Chance of Rise‘ using last ten years data
Predict average return on Regeneron Pharmaceuticals Stock Return: AI Predicts REGN Average and Excess Return After a Fall or Rise
Regeneron Pharmaceuticals Stock Return (Recent) Comparison With Peers
21 Day Returns
While REGN stock may see lower levels, 2020 has created many pricing discontinuities which can offer attractive trading opportunities. For example, you’ll be surprised how counter-intuitive the stock valuation is for Zoetis vs. Regeneron.
Invest with Trefis Market Beating Portfolios
See all Trefis Price Estimates
Led by MIT engineers and Wall Street analysts, Trefis (through its dashboards platform dashboards.trefis.com) helps you understand how a company’s products, that you
Led by MIT engineers and Wall Street analysts, Trefis (through its dashboards platform dashboards.trefis.com) helps you understand how a company’s products, that you touch, read, or hear about everyday, impact its stock price. Surprisingly, the founders of Trefis discovered that along with most other people they just did not understand even the seemingly familiar companies around them: Apple, Google, Coca Cola, Walmart, GE, Ford, Gap, and others. This might include you though you may have invested money in these companies, or may have been working with one of them for years as an employee, or have consulted with them as an expert for a long time. You can play with assumptions, or try scenarios, as-well-as ask questions to other users and experts. The platform uses extensive data to show in a single snapshot what drives the value of a company’s business. Trefis is currently used by hundreds of thousands of investors, company employees, and business professionals.